Contributions
Abstract: P1183
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Background: Glial cells play a significant role in the neuroaxonal demise in multiple sclerosis (MS). In progressive MS, glial activation is thought to be one of the major mechanisms of disability progression. Therefore, in vivo assessment of the glial cell activity is, in the treatment era of primary progressive MS (PPMS), more important than ever. However, data regarding glial activation markers in PPMS patients are scarce.
Objectives: To test the association of cerebrospinal fluid (CSF) markers of glial activation; chitinase-3-like protein 1 (CHI3L1) and soluble variant of triggering receptor expressed on myeloid cells 2 (sTREM2), with markers of neuroaxonal damage marker (Neurofilament light chain, NfL) and clinical severity scores.
Methods: CSF samples from PPMS patients were collected in the university hospitals of Ulm, Freiburg and Rostock. sTREM2 levels were measured using an MSD-based ELISA, and CHI3L1 levels were measured using the previously reported ELISA, while the NfL were measured using SIMOA assay. Furthermore, clinical severity scores Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Scores (MSSS) and Age-Related Multiple Sclerosis Severity Score (ARMSS) were assessed.
Results: 63 PPMS patients were included (41 from Freiburg, 18 from Ulm and 4 from Rostock). Median age and disease duration were 49.5 and 3.0 years respectively (minimum-maximus: 32-78 and 0-39 years respectively). Median sTREM2 was 3.0 ng/ml (0.5-7.7), CHI3L1 was 174.8 ng/ml (71.7-453.1). Median NfL was 1155 pg/ml (322-3850). Both sTREM2 and CHI3L1 correlated with NfL (Spearman rho= 0.4 and 0.3, p < 0.01 and < 0.05 respectively). Moreover, sTREM2 correlated with CHI3L1 (Spearman rho= 0.4, p < 0.001). None of the CSF markers correlated with age, disease duration or clinical severity scores.
Discussion: In this multicentric study, glial markers (CHI3L1 and sTREM2) correlated with neuroaxonal damage. These findings are in line with the histopathological observations that show microglial activation over the course of the disease. Our results may reflect a part of the complex PPMS pathology.
Conclusion: CHI3L1 and sTREM2 may be candidate markers to reflect the degree of glial activation over the course of the disease and under different disease-modifying treatments.
Disclosure: From all authors: No conflict of interest to declare.
Abstract: P1183
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Background: Glial cells play a significant role in the neuroaxonal demise in multiple sclerosis (MS). In progressive MS, glial activation is thought to be one of the major mechanisms of disability progression. Therefore, in vivo assessment of the glial cell activity is, in the treatment era of primary progressive MS (PPMS), more important than ever. However, data regarding glial activation markers in PPMS patients are scarce.
Objectives: To test the association of cerebrospinal fluid (CSF) markers of glial activation; chitinase-3-like protein 1 (CHI3L1) and soluble variant of triggering receptor expressed on myeloid cells 2 (sTREM2), with markers of neuroaxonal damage marker (Neurofilament light chain, NfL) and clinical severity scores.
Methods: CSF samples from PPMS patients were collected in the university hospitals of Ulm, Freiburg and Rostock. sTREM2 levels were measured using an MSD-based ELISA, and CHI3L1 levels were measured using the previously reported ELISA, while the NfL were measured using SIMOA assay. Furthermore, clinical severity scores Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Scores (MSSS) and Age-Related Multiple Sclerosis Severity Score (ARMSS) were assessed.
Results: 63 PPMS patients were included (41 from Freiburg, 18 from Ulm and 4 from Rostock). Median age and disease duration were 49.5 and 3.0 years respectively (minimum-maximus: 32-78 and 0-39 years respectively). Median sTREM2 was 3.0 ng/ml (0.5-7.7), CHI3L1 was 174.8 ng/ml (71.7-453.1). Median NfL was 1155 pg/ml (322-3850). Both sTREM2 and CHI3L1 correlated with NfL (Spearman rho= 0.4 and 0.3, p < 0.01 and < 0.05 respectively). Moreover, sTREM2 correlated with CHI3L1 (Spearman rho= 0.4, p < 0.001). None of the CSF markers correlated with age, disease duration or clinical severity scores.
Discussion: In this multicentric study, glial markers (CHI3L1 and sTREM2) correlated with neuroaxonal damage. These findings are in line with the histopathological observations that show microglial activation over the course of the disease. Our results may reflect a part of the complex PPMS pathology.
Conclusion: CHI3L1 and sTREM2 may be candidate markers to reflect the degree of glial activation over the course of the disease and under different disease-modifying treatments.
Disclosure: From all authors: No conflict of interest to declare.